Cybin

Cybin, Inc. is an ethical biopharmaceutical company engaged in the development of therapeutics for patients to address a multitude of mental health issues. It is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for mental health disorders. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

SAN DIEGO, Feb. 15, 2022 /PRNewswire/ -- The Chopra Foundation (the "Foundation"), a not-for-profit organization founded by Dr. Deepak Chopra, dedicated to improving health and well-being, today announced a partnership with Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) ("Cybin"), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™". The Foundation is working closely with Cybin to support education and awareness about its groundbreaking research to harness the potential of psychedelic therapies in mental health.

The Chopra Foundation Announces Partnership with Cybin Inc. to Increase Education and Awareness of the Potential Use of Psychedelics in Supporting Well-Being and Mental Health

Field Trip Health Ltd

Mind Medicine MindMed

Media company Global Trac Solutions, Inc. (OTCP:PSYC) and authorities behind psychedelic news and information platform Psychedelic Spotlight, announced that Psychedelic Spotlight will host its first “CEO Roundtable” on Feb. 15. The event is scheduled to be streamed live on YouTube via The Psychedelic Investor channel, and will be moderated by James Hallifax, journalist and content director for Psychedelic Spotlight.

Cybin, MindMed, and Field Trip Health Headline PSYC's First CEO Round Table Event.

Cybin, Inc. (CYBN) CEO Douglas Drysdale on Q3 2022 Results - Earnings Call Transcript

Psychedelics company Cybin Inc. CYBN CYBN announced that the U.S. Patent and Trademark Office has granted U.S. patent 11,242,318 to the company's investigational deuterated dimethyltryptamine (“DMT”) compound CYB004. The allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT.

Cybin Receives U.S. Patent For Its Proprietary Compound To Treat Anxiety Disorders

Psychedelics company Cybin Inc. CYBN CYBN announced that the U.S. Patent and Trademark Office  has granted U.S. patent 11,242,318 to the company's investigational deuterated dimethyltryptamine (“DMT”) compound CYB004. The allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT.

Cybin Obtains U.S. Patent For Is Proprietary Compound Deuterated DMT Aimed At Treating Anxiety Disorders

TORONTO--(BUSINESS WIRE)--Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders

Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders

Africa's first cannabis-focused blank check company should list this year, aiming to acquire companies in a young industry, next to genetics and wearable health-device businesses reported Bloomberg.  The founder of South Africa's Cilo Cybin Pharmaceutical Ltd, Gabriel Theron, told Bloomberg his plans to sell shares in a special purpose acquisition company in Johannesburg this spring with the goal of raising at least 500 million rands ($32 million).

Cilo Cybin Founder Gabriel Theron Plans First African Cannabis SPAC

TORONTO--(BUSINESS WIRE)--Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022

Cybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022

Atai Life Sciences BV

COMPASS Pathways

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials.

5 Psychedelic Therapeutics Decisions Coming in 2022

On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines. Field Trip Receives Notice Of Patent Allowance For Proprietary Psychedelic Molecule Field Trip Health (NASDAQ:FTRP) received a notice of allowance for a US patent application covering FT-104, its flagship psychedelic drug candidate.

Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana

Cybin Inc (NASDAQ: CYBN) shares are trading higher after the company announced an Institutional Review Board granted approval for a Cybin-sponsored feasibility study using Kernel Flow technology to measure psychedelic effects on the brain. “By leveraging the Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during and after a psychedelic experience, and collect quantitative data as opposed to subjective patient reporting,” said Doug Drysdale, Cybin's Chief Executive Officer.

Why Cybin Shares Are Rising

TORONTO--(BUSINESS WIRE)--Institutional Review Board Approves Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

Institutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the Brain

TORONTO--(BUSINESS WIRE)--Cybin Provides 2021 Year End Summary

Cybin Provides 2021 Year End Summary

TORONTO--(BUSINESS WIRE)--Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Conference

Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Conference

TORONTO--(BUSINESS WIRE)--Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004

Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to announce that it has confirmed a scientific advice meeting with the UK Medical and Healthcare Products Regulatory Agency (“MHRA”) for the first quarter of calendar year 2022. This program milestone brings the Company closer toward advancing its lead investigational candidate CYB003 into clinical developm

Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder

Ameri Holdings

GH Research PLC

Jaguar Health

Seelos Therapeutics

The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S. As a result, the psychedelics market is projected to grow 12.4% annually, reaching $10.75 billion in 2027.

9 Psychedelic Stocks to Watch For 2022

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will present at the Stifel GMP 2nd Annual Future of Healthcare Conference being held virtually on Wednesday, December 8, 2021. Mr. Drysdale's presentation will be webcast live on December 8, 2021 at 3:30 p.m. ET. To listen to the event, pleas

Cybin to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021

The FDA authorized an investigator-initiated Phase 2 trial evaluating Cybin Inc's (NYSE: CYBN) psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress. The trial will be conducted at the University of Washington.

Cybin To Test Psychedelic-Assisted Psychotherapy For COVID-Related Distress

TORONTO--(BUSINESS WIRE)--Cybin Announces FDA Investigational New Drug Approval for Phase 2 Clinical Trial for Frontline Clinicians Experiencing COVID-Related Distress

Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress

TORONTO--(BUSINESS WIRE)--Cybin to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021

Cybin to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021

Psychedelic therapy company, Cybin Inc. (NEO: CYBN) (NYSE:CYBN), recently announced it was awarded a grant for the first psychedelic treatment clinic at New York City's Lenox Hill Hospital with which it will provide care to marginalized and underserved communities on Manhattan's Upper East Side.  “Lenox Hill Hospital is excited by the potential of these modalities for the treatment of previously intractable conditions such as severe depression, chronic PTSD, and OCD,” said Dr. David Roane, chairman of psychiatry at Lenox Hill Hospital.

NY's Lenox Hill Hospital With Cybin-Awarded Grant Will Provide Psychedelic Therapy To City's Underserved

TORONTO--(BUSINESS WIRE)--Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities

Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities

Cybin, Inc. (CYBN) CEO Doug Drysdale on Q2 2022 Results - Earnings Call Transcript

Toronto-based, Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics,” reported its unaudited financial results on Monday for the second quarter ended September 30, 2021. Second-Quarter Financial Highlights

News for Cybin Stock (CYBN)